European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

The register

Every trial record behind this publication, one ray per row, and the newest reach furthest. Rays are placed by start date, or by the trial's first regulatory decision where the registry publishes no start date; 5 rows with neither sits short by the origin.

NCT05032833Phase 1 · Pharmacokinetics in Healthy AdultsNCT05347849Phase 1 · Pharmacokinetics in Healthy Adults2024-517747-31-00Phase 2 · Depressive disorder comorbid with cancerNCT05624268Phase 3 · Treatment Resistant DepressionNCT05660642Phase 2 · Treatment Resistant DepressionNCT05711940Phase 3 · Treatment Resistant DepressionNCT05804708Phase 2 · Postpartum Depression; Postnatal Depression2023-510047-37-00Phase 2 · Treatment-resistant depression (TRD)NCT05839509Phase 2 · Bipolar II DisorderNCT05800860Phase 2 · Treatment-resistant DepressionNCT05674929Phase 2 · Alcohol Use Disorder2024-517497-17-01Phase 2 · Alcohol Use Disorder2024-513457-70-00Phase 2 · Treatment-Resistant Depression (TRD)2024-518061-10-00Phase 2 · Severe Alcohol Use DisorderNCT05870540Phase 2 · Treatment Resistant Depression2023-505268-12-00Phase 3 · Treatment-resistant depression2022-501857-35-00Phase 2 · treatment-resistant depressionNCT06511947Phase 1 · Healthy VolunteersNCT06741228Phase 3 · Generalized Anxiety DisorderNCT06524830Phase 2 · Treatment Resistant Depression2024-516890-63-00Phase 2 · FibromyalgiaNCT06809595Phase 3 · Generalized Anxiety Disorder2023-503617-30-02Phase 1 · Coma and other disorders of consciousness due to acute traumatic and non-traumatic brain injuryNCT06941844Phase 3 · Major Depressive Disorder2023-510488-36-01Phase 2 · Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).2024-518218-24-00Phase 2 · Prolonged grief disorderNCT06605105Phase 3 · Major Depressive Disorder2024-513572-17-00Phase 3 · Generalized Anxiety Disorder (GAD)NCT07219966Phase 3 · Alcohol Use DisorderNCT07219953Phase 3 · Alcohol Use DisorderNCT07219173Phase 2 · Asthma2024-516936-93-02Phase 2 · chemotherapy-induced peripheral neuropathy, chronic neuropathic pain2024-519270-40-00Phase 3 · Major Depressive DisorderNCT07286175Phase 2 · Bipolar DisorderNCT06793397Phase 3 · Major Depressive Disorder (MDD); Depression in Adults and 4 more2024-515163-63-00Phase 2 · Anorexia Nervosa2024-519844-34-03Phase 2 · Treatment Resistant Depression (TRD)NCT05474989Phase 2 · Alcohol Use Disorder (AUD)NCT07412756Phase 3 · Depressive Disorder, Major2025-522640-41-00Phase 2 · Uncontrolled moderate to severe asthmaNCT07420283Phase 2 · Opioid Use Disorder2025-522312-16-00Phase 3 · Alcohol Use Disorder2025-522313-38-00Phase 3 · Alcohol Use DisorderNCT07540494Phase 1 · Healthy AdultNCT07545772Phase 2 · Irritable Bowel Syndrome; ConstipationNCT07545759Phase 2 · Irritable Bowel Syndrome; DiarrheaNCT07592689Phase 3 · Major Depressive Disorder2025-521488-11-00Phase 2 · Posttraumatic stress disorder2024-516805-22-00Phase 3 · Major Depressive DisorderNCT07210112Phase 2 · Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)2024-512911-34-00Phase 2 · Treatment-resistant depressionNCT07169747Phase 2 · Anorexia Nervosa2025-524939-39-02Phase 2 · Anorexia nervosaNCT07759245Phase 2 · Pulmonary Disease, Chronic Obstructive2025-524974-41-00Phase 2 · Irritable Bowel Syndrome - ConstipationNCT07444788Phase 1 · 5-methoxy-dimethyltryptamine (5-MeO-DMT)NCT07775300Phase 3 · Depressive Disorder, Major2025-523346-27-00Phase 2 · Treatment-Resistant Depression2025-524973-17-00Phase 2 · Irritable Bowel Syndrome Diarrhea2024-515184-65-01Phase 2 · Post-traumatic stress disorder2023-505532-35-00Phase 2 · Major Depressive Disorder, Malignant tumours ICD 10 C00 to C97NCT07824973NA · Treatment Resistant Depression (TRD)2025-522310-24-00Phase 3 · Depressive Disorder, MajorNCT07792538Phase 2 · Posttraumatic Stress Disorder (PTSD)2026-525480-41-00Phase 2 · Pulmonary Disease, Chronic ObstructiveNCT07570654Phase 3 · PTSD - Post Traumatic Stress Disorder; PTSD and 2 moreNCT07391332Phase 2 · Gambling DisorderNCT07871877Phase 2 · Opioid Use Disorder; Opioid Withdrawal and 1 moreNCT07877987Phase 1 · Psilocybin Intoxication2024-515147-32-02Phase 2 · Cocaine addiction2025-522743-18-00Phase 2 · Gambling disorder2023-503617-30-01Phase 2 · Coma and other disorders of consciousness due to acute traumatic and non-traumatic brain injury2024-520319-42-01Phase 2 · Major Depressive Disorder2025-520906-36-00Phase 2 · Attention Deficit Hyperactivity Disorder (ADHD)2025-522961-31-00Phase 2 · Depression2025-522961-31-01Phase 2 · Depression

76 records, read from primary registries. The table

Who is running the trials

Trials

Every psychedelic trial with a European site, read from the registries, not the press.

EU Clinical Trials Information System 37

Member states whose regulator has a decision on the trial. CTIS publishes no primary completion date.

RecordAssetPhaseIndicationStatusMember states concernedVerified
2023-505268-12-00COMP360Therapeutic confirmatory (Phase III)Treatment-resistant depressionAuthorisedCzechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden2026-08-31
2023-510047-37-00GH001Therapeutic exploratory (Phase II)Treatment-resistant depression (TRD)EndedCzechia, Germany, Ireland, Poland, Spain2026-08-31
2024-513457-70-00BPL-003Therapeutic exploratory (Phase II)Treatment-Resistant Depression (TRD)EndedGermany, Poland, Spain2026-08-31
2024-513572-17-00DT120 (registry title MM120)Therapeutic confirmatory (Phase III)Generalized Anxiety Disorder (GAD)AuthorisedCzechia, France, Germany, Poland2026-08-31
2024-515163-63-00psilocybin (investigator-led)Therapeutic exploratory (Phase II)Anorexia NervosaAuthorisedSweden2026-10-19
2024-516805-22-00HLP003Therapeutic confirmatory (Phase III)Major Depressive DisorderAuthorisedCzechia, Germany, Greece, Ireland, Poland2026-08-31
2025-522310-24-00brenipatide (LY3537031)Therapeutic confirmatory (Phase III)Depressive Disorder, MajorAuthorisedGermany, Greece, Poland, Spain2026-10-19
2025-522312-16-00brenipatide (LY3537031)Therapeutic confirmatory (Phase III)Alcohol Use DisorderAuthorisedBelgium, Germany2026-11-07
2025-522313-38-00brenipatide (LY3537031)Therapeutic confirmatory (Phase III)Alcohol Use DisorderAuthorisedBelgium, Germany2026-08-31
2025-524973-17-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Irritable Bowel Syndrome DiarrheaAuthorisedBelgium, Germany, Poland, Spain2026-08-31
2025-524974-41-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Irritable Bowel Syndrome - ConstipationAuthorisedBelgium, Spain2026-08-31
2025-521488-11-00psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)Therapeutic exploratory (Phase II)Posttraumatic stress disorderAuthorisedNetherlands2026-09-08
2025-524939-39-02psilocybin (investigator-led; PEX010)Therapeutic exploratory (Phase II)Anorexia nervosaAuthorisedDenmark2026-09-08
2025-523346-27-00psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico)Therapeutic exploratory (Phase II)Treatment-Resistant DepressionAuthorisedItaly2026-09-08
2024-515184-65-01MDMA hydrochloride (investigator-led)Therapeutic exploratory (Phase II)Post-traumatic stress disorderAuthorisedNetherlands2026-09-08
2025-522640-41-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Uncontrolled moderate to severe asthmaAuthorisedGermany, France, Netherlands, Poland2026-09-15
2026-525480-41-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Pulmonary Disease, Chronic ObstructiveAuthorisedAustria, Czechia, Germany, Denmark, France, Hungary, Poland, Romania2026-11-07
2023-510488-36-01noneTherapeutic exploratory (Phase II)Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).AuthorisedCzechia, Denmark, Netherlands, Portugal2026-11-07
2024-517747-31-00noneTherapeutic exploratory (Phase II)Depressive disorder comorbid with cancerAuthorisedCzechia2026-09-28
2024-519270-40-00HLP003Therapeutic confirmatory (Phase III)Major Depressive DisorderAuthorisedCzechia, Germany, Greece, Ireland, Poland2026-11-07
2022-501857-35-00noneTherapeutic exploratory (Phase II)treatment-resistant depressionAuthorisedBelgium2026-10-19
2023-503617-30-01nonePhase I and Phase II (Integrated)- OtherComa and other disorders of consciousness due to acute traumatic and non-traumatic brain injuryNot authorisedDenmark2026-10-19
2023-503617-30-02noneHuman Pharmacology (Phase I)- OtherComa and other disorders of consciousness due to acute traumatic and non-traumatic brain injuryAuthorisedDenmark2026-10-19
2023-505532-35-00noneTherapeutic exploratory (Phase II)Major Depressive Disorder, Malignant tumours ICD 10 C00 to C97AuthorisedSweden2026-10-19
2024-512911-34-00noneTherapeutic exploratory (Phase II)Treatment-resistant depressionAuthorisedFrance2026-10-19
2024-515147-32-02noneTherapeutic exploratory (Phase II)Cocaine addictionAuthorisedIreland2026-10-19
2024-516890-63-00noneTherapeutic exploratory (Phase II)FibromyalgiaAuthorisedNetherlands2026-10-19
2024-516936-93-02noneTherapeutic exploratory (Phase II)chemotherapy-induced peripheral neuropathy, chronic neuropathic painAuthorisedNetherlands2026-10-19
2024-517497-17-01nonePhase I and Phase II (Integrated)- OtherAlcohol Use DisorderEndedDenmark2026-10-19
2024-518061-10-00noneTherapeutic exploratory (Phase II)Severe Alcohol Use DisorderAuthorisedBelgium2026-10-19
2024-518218-24-00noneTherapeutic exploratory (Phase II)Prolonged grief disorderAuthorisedSweden2026-10-19
2024-519844-34-03noneTherapeutic exploratory (Phase II)Treatment Resistant Depression (TRD)AuthorisedItaly2026-10-19
2024-520319-42-01noneTherapeutic exploratory (Phase II)Major Depressive DisorderAuthorisedNorway2026-10-19
2025-520906-36-00noneTherapeutic exploratory (Phase II)Attention Deficit Hyperactivity Disorder (ADHD)Not authorisedNetherlands2026-10-19
2025-522743-18-00noneTherapeutic exploratory (Phase II)Gambling disorderAuthorisedFrance2026-10-19
2025-522961-31-00noneTherapeutic exploratory (Phase II)DepressionNot authorisedDenmark2026-10-19
2025-522961-31-01noneTherapeutic exploratory (Phase II)DepressionAuthorisedDenmark2026-10-19

ClinicalTrials.gov 39

The sponsor's registered location list, which states intent rather than approval.

RecordAssetPhaseIndicationStatusRegistered countriesVerified
NCT05347849BPL-003PHASE1Pharmacokinetics in Healthy AdultsCOMPLETEDUnited Kingdom2026-08-31
NCT05624268COMP360PHASE3Treatment Resistant DepressionCOMPLETEDUnited States2026-08-31
NCT05660642BPL-003PHASE2Treatment Resistant DepressionRECRUITINGUnited Kingdom2026-08-31
NCT05674929BPL-003PHASE2Alcohol Use DisorderCOMPLETEDUnited Kingdom2026-08-31
NCT05711940COMP360PHASE3Treatment Resistant DepressionACTIVE_NOT_RECRUITINGCanada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United Kingdom, United States2026-08-31
NCT05800860GH001PHASE2Treatment-resistant DepressionCOMPLETEDCzechia, Germany, Ireland, Netherlands, Poland, Spain2026-08-31
NCT05804708GH001PHASE2Postpartum Depression;Postnatal DepressionTERMINATEDNetherlands, United Kingdom2026-08-31
NCT05839509GH001PHASE2Bipolar II DisorderTERMINATEDGermany, Netherlands, United Kingdom2026-08-31
NCT05870540BPL-003PHASE2Treatment Resistant DepressionCOMPLETEDAustralia, Germany, Poland, Spain, United Kingdom, United States2026-09-15
NCT06524830VLS-01PHASE2Treatment Resistant DepressionCOMPLETEDAustralia, Canada, United Kingdom, United States2026-11-02
NCT06605105HLP003PHASE3Major Depressive DisorderENROLLING_BY_INVITATIONAustralia, Greece, Poland, United Kingdom, United States2026-10-13
NCT06741228DT120 (registry title MM120)PHASE3Generalized Anxiety DisorderACTIVE_NOT_RECRUITINGUnited States2026-09-15
NCT06793397HLP003PHASE3Major Depressive Disorder (MDD);Depression in Adults;Depression - Major Depressive Disorder;Depression Disorders;Depression Disorder;DepressionRECRUITINGAustralia, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, United States2026-10-06
NCT06809595DT120 (registry title MM120)PHASE3Generalized Anxiety DisorderACTIVE_NOT_RECRUITINGCzechia, France, Germany, Poland, United Kingdom, United States2026-09-08
NCT06941844DT120 (registry title MM120)PHASE3Major Depressive DisorderACTIVE_NOT_RECRUITINGUnited States2026-08-31
NCT07169747psilocybin (investigator-led)PHASE2Anorexia NervosaRECRUITINGSweden2026-08-31
NCT07286175brenipatide (LY3537031)PHASE2Bipolar DisorderRECRUITINGArgentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States2026-08-31
NCT07412756brenipatide (LY3537031)PHASE3Depressive Disorder, MajorRECRUITINGAustralia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States2026-11-07
NCT07592689DT120 (registry title MM120)PHASE3Major Depressive DisorderRECRUITINGUnited States2026-08-31
NCT07775300brenipatide (LY3537031)PHASE3Depressive Disorder, MajorRECRUITINGAustralia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States2026-10-19
NCT07792538psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)PHASE2Posttraumatic Stress Disorder (PTSD)NOT_YET_RECRUITINGNetherlands2026-09-08
NCT07824973noneNATreatment Resistant Depression (TRD)NOT_YET_RECRUITINGSweden2026-09-22
NCT07210112nonePHASE2Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)RECRUITINGFrance2026-09-22
NCT07759245brenipatide (LY3537031)PHASE2Pulmonary Disease, Chronic ObstructiveRECRUITINGArgentina, Austria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, United Kingdom, United States2026-09-28
NCT07219953brenipatide (LY3537031)PHASE3Alcohol Use DisorderRECRUITINGBelgium, China, Germany, Japan, South Korea, Taiwan, United Kingdom, United States2026-11-07
NCT07219966brenipatide (LY3537031)PHASE3Alcohol Use DisorderRECRUITINGBelgium, China, Germany, Japan, South Korea, Taiwan, United Kingdom, United States2026-09-28
NCT07545772brenipatide (LY3537031)PHASE2Irritable Bowel Syndrome; ConstipationRECRUITINGBelgium, Canada, China, Japan, Mexico, Spain, United Kingdom, United States2026-09-28
NCT07545759brenipatide (LY3537031)PHASE2Irritable Bowel Syndrome; DiarrheaRECRUITINGBelgium, Canada, China, Germany, Japan, Mexico, Poland, Spain, United Kingdom, United States2026-09-28
NCT07219173brenipatide (LY3537031)PHASE2AsthmaRECRUITINGArgentina, Brazil, Canada, China, France, Germany, India, Japan, Mexico, Netherlands, Poland, United States2026-11-07
NCT07420283brenipatide (LY3537031)PHASE2Opioid Use DisorderRECRUITINGCanada, Puerto Rico, United Kingdom, United States2026-11-07
NCT05032833BPL-003PHASE1Pharmacokinetics in Healthy AdultsCOMPLETEDUnited Kingdom2026-10-13
NCT07570654COMP360PHASE2;PHASE3PTSD - Post Traumatic Stress Disorder;PTSD;PTSD Symptoms;PTSD, Post Traumatic Stress DisorderRECRUITINGCanada, United States2026-11-07
NCT07391332nonePHASE2Gambling DisorderRECRUITINGFrance2026-10-19
NCT06511947GH001PHASE1Healthy VolunteersTERMINATEDUnited Kingdom2026-10-19
NCT07540494GH001PHASE1Healthy AdultCOMPLETEDUnited States2026-10-19
NCT05474989nonePHASE2Alcohol Use Disorder (AUD)RECRUITINGSwitzerland2026-10-19
NCT07444788nonePHASE15-methoxy-dimethyltryptamine (5-MeO-DMT)RECRUITINGSwitzerland2026-10-19
NCT07871877nonePHASE1;PHASE2Opioid Use Disorder;Opioid Withdrawal;Substance Use DisordersNOT_YET_RECRUITINGUnited States2026-10-19
NCT07877987nonePHASE1Psilocybin IntoxicationNOT_YET_RECRUITINGUnited States2026-10-19